Private capital is flowing into the sector earlier, targeting younger companies with built-in platform potential.
Private capital is poised to remain a driving force in healthcare and life sciences, even as the sector navigates a more complex and competitive environment. After a record-setting surge in 2024 — when global healthcare private equity reached an estimated $103 billion in cumulative deal flow, the third-highest year on record — 2025 reinforced the trend with investors continuing to rewrite the rules amid regulatory disruption, political volatility, and a rapidly evolving biotech landscape.
